The Second Chance at Life Act of 2025 would add a new Title XXXIV to the Public Health Service Act requiring that patients seeking a two‑drug medical abortion (mifepristone followed by misoprostol) receive explicit oral and written information that it "may be possible" to reverse the effects of mifepristone if they change their mind. The statute also requires conspicuous clinic signage, directs the Secretary of HHS to publish multilingual printed materials and maintain a specified website, and gives fathers, parents and treated patients a private right to sue providers who knowingly or recklessly violate the new disclosure rules.
Why this matters: the bill converts a contested clinical claim into a federally mandated disclosure and backs compliance with private civil remedies. That changes clinical workflows (including telemedicine), creates new administrative tasks for HHS, and exposes abortion providers to novel federal liability while leaving states free to impose even stricter disclosure rules.
At a Glance
What It Does
The bill requires physicians (or their agents) to inform a woman at least 24 hours before a mifepristone‑based chemical abortion that reversal may be possible and to provide a specified written discharge statement after the first drug is dispensed. It mandates clinic signage, directs HHS to publish materials and operate a website with technical formatting rules, and creates a federal private right of action for certain plaintiffs against providers who knowingly or recklessly violate the statute.
Who It Affects
Abortion providers in all settings (private offices, clinics, hospitals) and providers who prescribe medication abortions across state lines, HHS (which must produce materials and host the website), and patients — as well as fathers and parents who may now sue. Telemedicine services and pharmacies that dispense the first pill will need new protocols.
Why It Matters
The bill changes the compliance baseline for medication abortion at the federal level and attaches civil liability to disclosure failures, amplifying legal risk for clinicians and operators. It also imposes specific operational and technical requirements on HHS and facilities that are atypical for health guidance.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The Act amends the Public Health Service Act by inserting a new Title XXXIV focused on "abortion pill reversal" disclosures. At the patient level it creates a two‑part obligation for chemical abortions that use the two‑drug mifepristone‑then‑misoprostol regimen.
First, at least 24 hours before the abortion the patient must be told, by phone or in person, by the treating or referring physician or that physician’s agent, that it may be possible to reverse the effects of mifepristone if she changes her mind and that time is of the essence. Second, after the first drug is dispensed the physician must give a required written discharge statement containing specific language telling the patient that mifepristone alone is not always effective and that reversal may be possible if the second pill has not been taken.
Facilities that provide chemical abortions (except where an emergency exception applies) must conspicuously post a prescribed sign in waiting and consultation rooms or admission areas; the Act specifies minimum type size and legibility. The statute establishes a medical emergency exception for life‑threatening conditions and requires the abortion provider who determines an emergency to place a written certification of the specific medical circumstances in the patient’s medical file.On the administrative side the Secretary of Health and Human Services must publish printed materials in English and any language that is the primary language of at least 2 percent of a State’s population and must maintain a website within 30 days of enactment with the same information.
The bill prescribes technical specifications for the website (minimum DPI, image pixel size, font size, browser compatibility) and forbids the collection of information about who uses the site while requiring active monitoring to prevent tampering.Enforcement is civil: a patient who underwent or attempted to undergo a chemical abortion, the father of the unborn child, or a parent of a minor patient may sue a provider in federal district court for actual and punitive damages if the provider knowingly or recklessly violated the title. Courts must award reasonable attorney’s fees to prevailing plaintiffs and may award fees to prevailing defendants when a suit is frivolous; plaintiffs are barred if the pregnancy resulted from the plaintiff’s criminal conduct.
The Act also contains an express savings clause allowing states to retain or impose more extensive disclosure and penalty rules, and a severability provision.
The Five Things You Need to Know
Compliance is effective 30 days after enactment: providers must meet the law’s disclosure, signage and recordkeeping duties starting then.
The oral disclosure must occur at least 24 hours before the chemical abortion and may be delivered by the treating or referring physician or an agent by phone or in person.
After dispensing mifepristone the physician must give a specific written discharge statement that reproduces the statutory language about possible reversal if the second pill has not been taken.
HHS must publish printed materials in English and any language that is primary for ≥2% of a State’s population and launch a website within 30 days; the statute prescribes technical formatting (70 DPI minimum, images 200x300 pixels, 12‑point font, no plug‑ins) and forbids collecting user information.
The Act creates a federal private right of action: the treated patient, the fetal father, or a parent of a minor can sue for actual and punitive damages against providers who knowingly or recklessly violated the title, with prevailing‑party fee rules.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Definitions — who and what the law covers
This section defines key terms: 'abortion provider' as any person licensed under applicable federal or state law, 'chemical abortion' as use or prescription of an abortion‑inducing drug intended to cause fetal death, 'unborn child' as a member of Homo sapiens prior to birth, and 'woman' broadly. These definitions frame scope: the law reaches licensed clinicians in all settings and ties obligations to a two‑drug mifepristone‑first process.
Informed‑consent content and timing
Section 3402 establishes the core patient obligations: an oral notification at least 24 hours prior and a mandatory written discharge statement after mifepristone is dispensed. The statute specifies who may deliver the verbal notice (treating/referring physician or an agent) and reproduces the exact written language to be provided. Practically, clinics must incorporate new scripting, documentation of the 24‑hour contact, and a discharge form capturing the required sentence.
Emergency exception and certification requirement
The statute exempts cases where a physician certifies that the abortion is necessary to save the woman’s life because of a life‑endangering physical disorder, injury, or illness. Providers invoking the exception must place a truthful, accurate certification of the specific medical circumstances in the patient’s file, creating a contemporaneous record that can be reviewed in subsequent disputes.
Mandatory clinic signage and formatting rules
Facilities that perform non‑emergency chemical abortions must post a conspicuous sign with specified text in waiting rooms, consultation rooms, or admission areas depending on facility type. The law prescribes minimum bold type size (at least ¾‑inch) and legibility standards, which will require clinics to standardize signage placement and procurement and to incorporate compliance checks into intake workflows.
HHS materials and website with technical specifications
The Secretary must publish printable informational materials in English and in any language that is the primary language of 2% or more of a State’s population, and must host a website with the same information within 30 days of enactment. The statute uniquely prescribes technical attributes — minimum 70 DPI, images at least 200x300 pixels, 12‑point font, browser compatibility, prohibition on collecting user data, and ongoing monitoring to prevent tampering — shifting specific design and operational responsibilities to HHS.
Private civil enforcement, damages, and fee shifting
This section authorizes federal district‑court lawsuits by the treated patient, the father of the unborn child, or a parent of a minor patient for actual and punitive damages where a provider 'knowingly or recklessly' violated the title. The section bars suits when the pregnancy results from the plaintiff’s criminal conduct, requires fee awards to prevailing plaintiffs, and allows fee awards to prevailing defendants where suits are frivolous. That creates a mechanism for private enforcement rather than administrative penalties.
State law interaction and severability
The preemption clause preserves state laws that impose more extensive disclosure requirements or penalties; it does not displace stricter state regimes. The severability clause ensures the remainder of the Act survives if parts are found unconstitutional. Operationally this means providers must track both the federal baseline and any applicable state mandates, which could vary across jurisdictions.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Patients who wish to know about and attempt an intervention after receiving mifepristone: the law guarantees a standardized verbal and written disclosure and points patients to HHS materials and a federal website that collects no user data.
- Fathers and parents of minor patients: the statute expressly grants them standing to bring federal suits for disclosure failures, giving them an enforcement tool they did not have under typical informed‑consent regimes.
- States and advocacy groups favoring additional abortion disclosures: the preemption clause preserves and validates state laws that impose more extensive disclosure or penalties, protecting state flexibility.
Who Bears the Cost
- Abortion providers (clinics, private offices, hospitals and telemedicine prescribers): they must change intake workflows, train staff to deliver and document the 24‑hour oral notice, supply the exact written discharge language, post prescribed signage, and face increased exposure to federal civil litigation and potential punitive damages.
- HHS and its contractors: the agency must produce multilingual materials and launch a specified website within 30 days and maintain active monitoring and technical specifications, creating immediate operational and budgetary demands.
- Telemedicine platforms and pharmacies that dispense mifepristone: they will need protocols for timing, documentation, and either to avoid dispensing where the 24‑hour rule is not met or to redesign care pathways, potentially restricting remote medication abortion access.
Key Issues
The Core Tension
The central dilemma is between protecting a patient's access to a specific piece of information (and creating private enforcement to ensure its delivery) and imposing federal, litigation‑backed obligations that require clinicians and HHS to disseminate and operationalize a contested clinical claim — a trade‑off between patient disclosure and clinician discretion, with legal exposure as the balancing mechanism.
Several implementation and legal questions are left unresolved. The statute conditions liability on a provider acting 'knowingly or recklessly' but does not define those standards in clinical terms; courts will need to sort whether a failure to deliver the statutory script is reckless or whether a provider exercising clinical judgment falls within the exception for medical emergencies.
The HHS website and printed materials must be produced quickly (30 days) and must meet specific formatting rules that are atypical for health guidance; that creates procurement and operational friction, and the ban on collecting user data raises questions about how HHS will monitor access and usage without analytics.
The private civil‑enforcement model shifts oversight from administrative regulators to federal courts and invites litigation over causation, standing and damages — for example, how a father establishes Article III standing and causal injury tied to a disclosure omission. The law's textual focus on the mifepristone‑first two‑drug regimen raises cross‑jurisdictional issues for telemedicine prescriptions and mail‑order dispensing where state law or logistics may not align with the 24‑hour in‑person or phone contact requirements.
Finally, the statute compels providers to deliver a uniform message about a contested clinical claim and prescribes written language and signage specifications, which could produce conflicts where clinical evidence, institutional policy, or professional guidance diverge from the mandated text.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.